# Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

> **NCT03572933** · PHASE3 · COMPLETED · sponsor: **Marinus Pharmaceuticals** · enrollment: 101 (actual)

## Conditions studied

- CDKL5 Deficiency Disorder

## Interventions

- **DRUG:** ganaxolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03572933
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-30
- **Primary completion:** 2020-07-31
- **Final completion:** 2021-05-28
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572933, "Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03572933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*